Investors
Information Disclosure
-
VOLUNTARY ANNOUNCEMENT - SHARE PURCHASE PURSUANT TO RESTRICTED SHARE AWARD SCHEME2024.04.19
-
VOLUNTARY ANNOUNCEMENT - CATEGORY 1 INNOVATIVE DRUG "ROVADICITINIB (TQ05105)" OBTAINED POSITIVE RESULTS IN KEY CLINICAL RESEARCH FOR REGISTRATION2024.04.18
-
VOLUNTARY ANNOUNCEMENT - SHARE PURCHASE PURSUANT TO RESTRICTED SHARE AWARD SCHEME2024.04.17
-
NEXT DAY DISCLOSURE RETURN2024.04.16
-
VOLUNTARY ANNOUNCEMENT - SHARE PURCHASE PURSUANT TO RESTRICTED SHARE AWARD SCHEME2024.04.15
-
VOLUNTARY ANNOUNCEMENT - SHARE PURCHASE PURSUANT TO RESTRICTED SHARE AWARD SCHEME2024.04.12
-
VOLUNTARY ANNOUNCEMENT - PRESENTATION OF THE PHASE II CLINICAL STUDY DATA ON KRAS G12C INHIBITOR “GARSORASIB TABLET (D-1553)”2024.04.11
-
VOLUNTARY ANNOUNCEMENT - DATA OF 6 STUDIES REGARDING “ANLOTINIB HYDROCHLORIDE CAPSULES”, “TQB2916 (CD40 AGONIST)” AND “FHND6091 (PROTEASOME INHIBITOR)” WERE PRESENTED AT 2024 AACR2024.04.10